What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Fibonacci Extensions

Score

-0.7

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 8 37.6 0.38% 0.60% 126.8% -9.3% 333.9%
SHORT 9 41.9 0.33% 0.50% 3.9% -13.0% -66.6%

Summary

Technical Analysis

Opthea (OPT.AX)


Indicator:

FIBONACCI EXTENSION


Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.


Opthea (ASX:OPT) : The current Fibonacci Extension levels are:
(23.61%) $3.39
(38.2%) $3.27
(50%) $3.18
(61.8%) $3.08

The current support levels are:
(78.6%) $2.94
(100%) $2.77
(138.2%) $2.46
(161.8%) $2.27
(261.8%) $1.46
(423.61%) $0.15



Fibonacci extensions are used in Fibonacci retracement to predict spaces of resistance and support in the market. These extensions involve all levels drawn past the basic 100% level they are frequently used by traders to determine areas that will bring in profits.

Calculation: Fibonacci Extensions:
1) Uptrend: D = B — (A — B) x N%;
2) Downtrend: D = B + (B — A) x N %;
3) Fibonacci Levels:
61.8%
100%
138.2%
161.8%
261.8%
423.6%;


PROFILE: Opthea (OPT.AX)


Stock Exchange: ASX
Company: Opthea
Ticker Codes: | OPT.AX | ASX:OPT |

About Opthea (ASX:OPT):

Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Top 10:

Fibonacci Extensions

Download
Company Close Change(%) Volume Value Signal
RUL Runge 1.11 18.7 2,203,526 0.09 BULLISH
PNV Polynovo 2.83 11 8,785,749 0.1 BULLISH
DNA Donaco International 0.08 10.7 1,523,777 0.03 BULLISH
FMG Fortescue Metals 12.69 5 21,508,010 1.21 BULLISH
BBN Baby Bunting 3.6 4.7 637,354 1.32 BULLISH
CAJ Capitol Health 0.24 4.3 2,084,942 0.05 BULLISH
OSP Osprey Medical 0.03 3.7 57,495 0.03 BULLISH
NEA Nearmap 2.62 3.6 3,668,519 0.37 BULLISH
APZ Aspen 1.18 3.5 360 0.17 BULLISH
IFT Infratil 5.39 3.5 17,293 0.4 BULLISH